Nucleix Nabs CE Mark for Bladder EpiCheck

Mar 22, 2017

|

NEW YORK (GenomeWeb) – Nucleix said today that it has received a CE Mark for its Bladder EpiCheck test, which is intended to help urologists better monitor bladder cancer patients.

Bladder EpiCheck is a urine test that utilizes multiplexed real-time PCR to analyze a panel of 15 methylation markers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Nucleix Nabs CE Mark for Bladder EpiCheck

To read the full story....

Breaking News

CMS Releases New Guidance Requiring Payors to Cover COVID-19 Testing Without Cost Sharing

UPDATED: Quidel At-Home, Rapid Antigen, COVID-19 Test Gets FDA Emergency Use Authorization

FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

OpGen Unyvero IVD Platform Nabs Chinese Regulatory Approval

360Dx Index Declines 4 Percent in February, Ending Streak of Gains

What's Popular?

Hologic Acquires European MDx Firm Diagenode for Approximately $159M

Luminex Shares Surge on Rumor of Acquisition by DiaSorin

Guardant Health Begins First Foray Into Early-Stage Cancer With Commercial MRD Test Launch

Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

Adaptive Biotechnologies Touts New Era of T Cell-Based Dx With T-Detect COVID Launch

Sponsorships